Research
Hormonal
Obesity is associated with an increased risk of differentiated thyroid cancer (DTC), potentially mediated by higher TSH levels, insulin/IGF-1 pathways, and adipokines like leptin.
Obesity is linked to a higher risk of thyroid cancer. This may be due to higher TSH, insulin, and fat-derived hormones. Maintaining a healthy weight may help reduce this risk.
ModerateSupportsMEDIUM confidence
A systematic review of prospective observational studies showed a positive association between BMI categories at diagnosis and the risk of developing DTC... The mechanisms underlying this hypothetical association remain largely unclear, but the increased serum level of TSH, frequently observed in obese patients, might play a role.
Why this rating
Based on observational studies and meta-analyses; causal mechanisms are 'largely unclear' and 'hypothetical'.
Source
MECHANISMS IN ENDOCRINOLOGY: The crosstalk between thyroid gland and adipose tissue: signal integration in health and disease
Ferruccio Santini et al. · European Journal of Endocrinology · 2014
DOI 10.1530/eje-14-0067
narrative_reviewCited 230×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In euthyroid obese individuals, elevated serum TSH is an adaptive physiological response to increased thyroid hormone disposal driven by larger body size, rather than primary hypothyroidism.Good
- Leptin acts as a critical signal from adipose tissue to the hypothalamus to regulate the hypothalamus-pituitary-thyroid axis, specifically by stimulating TRH expression and TSH secretion during energy sufficiency.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →